Monroe Backs BelHealth Buy of Precision Toxicology
Search
Share on twitter
Share on linkedin
Share on print
Share on email

Monroe Backs BelHealth Buy of Precision Toxicology

monroe nf4Monroe Capital was the sole lead arranger and administrative agent on a $14.5 million senior credit facility to support the recapitalization and growth of Precision Toxicology by BelHealth Investment Partners.

Dave Sturek nf1“We are pleased to partner with Monroe Capital on this transaction,” said Dave Sturek, Managing Director of BelHealth. “Their group is highly experienced in the healthcare industry and we look forward to working with them to help Precision Toxicology continue its strong growth trajectory and become a national competitor in the clinical diagnostic segment.”

Precision Toxicology is a clinical laboratory that specializes in providing quantitative drug testing, primarily for the purpose of helping physicians monitor their patients undergoing treatment for pain or substance abuse. Precision’s objective is to improve patient adherence and compliance with their prescription regimen and protect medical practices from liability. Precision Toxicology is headquartered in San Diego (www.precisiontoxicology.com).

BelHealth Investment Partners is a lower middle market healthcare focused private equity firm.  The firm invests from $20 million to $40 million in companies in four healthcare segments: services, distribution, products, and information technology. BelHealth is based in New York (www.belhealth.com)

Monroe Capital provides senior and junior debt and equity co-investments to middle-market companies. The firm was founded in 2004 and maintains offices in Chicago, Atlanta, Boston, Charlotte, Dallas, Los Angeles, New York and San Francisco (www.monroecap.com).

© 2015 PEPD • Private Equity’s Leading News Magazine • 4-2-15

Share on twitter
Share on linkedin
Share on print
Share on email

To search in site, type your keyword and hit enter